<p>明尼苏达州查斯卡，2026 年 1 月 16 日（全球新闻稿）——Lifecore Biomedical, Inc.（纳斯达克：LFCR）（“Lifecore”）是一家全面整合的合同开发和制造组织（“CDMO”），今天宣布在 2026 年 1 月 14 日，Lifecore 薪酬委员会批准了根据 Lifecore 的股权诱导计划（经修订）（“诱导计划”）授予的限制性股票单位（“RSU”）奖励，涉及其普通股总计 1,738 股，以及股票期权总计 8,775 股，授予两名新聘员工。RSU 奖励和股票期权于 2026 年 1 月 14 日根据 Lifecore 与每位员工之间的聘用信授予，并作为每位员工加入 Lifecore 的重要诱因。</p>
<p>RSU 奖励和股票期权由 Lifecore 的薪酬委员会批准，并根据诱导计划作为诱导股权奖励授予，符合纳斯达克上市规则 5635(c)(4)。</p>
<p>RSU 将在授予日期的第三周年时归属并结算，前提是持续就业。股票期权的行使价格等于授予日期的公允市场价值（如诱导计划中定义），并将在授予日期的第一周年时归属三分之一的股份，之后每个月归属 1/36 的股份，前提是持续就业。股票期权的有效期为七年。RSU 奖励和股票期权均受奖励协议和诱导计划的约束。</p>
<p><strong>关于 Lifecore Biomedical</strong></p>
<p>Lifecore Biomedical, Inc.（纳斯达克：LFCR）是一家全面整合的合同开发和制造组织（CDMO），在无菌注射药物产品的开发、灌装和封装方面提供高度差异化的能力，包括复杂配方。作为优质注射级透明质酸的领先制造商，Lifecore 凭借超过 40 年的专业知识，成为全球和新兴生物制药及生物技术公司的合作伙伴，帮助他们在多个治疗类别中将创新推向市场。有关公司的更多信息，请访问 Lifecore 的网站 www.lifecore.com。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU56UXdPU00zTXpZMk1qRTRJekl3TURjM05UWT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU56UXdPU00zTXpZMk1qRTRJekl3TURjM05UWT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZDljZDcxYTctZThhMS00NDI5LTg2OGItMjFiNjE2NzNlY2EyLTEwMTkzMjktMjAyNi0wMS0xNi1lbg==/tiny/Lifecore-Biomedical-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZDljZDcxYTctZThhMS00NDI5LTg2OGItMjFiNjE2NzNlY2EyLTEwMTkzMjktMjAyNi0wMS0xNi1lbg==/tiny/Lifecore-Biomedical-Inc-.png"/></p>
<pre><code>Lifecore Biomedical, Inc. 联系信息：Stephanie Diaz（投资者）Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com Tim Brons（媒体）Vida Strategic Partners 415-675-7402 tbrons@vidasp.com Ryan D. Lake（首席财务官）Lifecore Biomedical 952-368-6244 ryan.lake@lifecore.com
</code></pre>

LFCR

<p>Lifecore Biomedical, Inc. 宣布根据纳斯达克上市规则 5635(c)(4) 批准对两名新聘员工的激励授予。授予包括 1,738 股限制性股票单位（RSUs）和 8,775 股股票期权，生效日期为 2026 年 1 月 14 日。限制性股票单位将在授予三周年时归属，而股票期权将在七年内逐步归属。Lifecore 是一家专注于无菌注射药品的合同开发和制造组织</p>

<p>CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to two newly hired employees of Lifecore. The RSU award and stock options were granted on January 14, 2026, pursuant to the offer letters between Lifecore and each employee, and as a material inducement to each employee joining Lifecore.</p>
<div class="lb-trans"><p>明尼苏达州查斯卡，2026 年 1 月 16 日（全球新闻稿）——Lifecore Biomedical, Inc.（纳斯达克：LFCR）（“Lifecore”）是一家全面整合的合同开发和制造组织（“CDMO”），今天宣布在 2026 年 1 月 14 日，Lifecore 薪酬委员会批准了根据 Lifecore 的股权诱导计划（经修订）（“诱导计划”）授予的限制性股票单位（“RSU”）奖励，涉及其普通股总计 1,738 股，以及股票期权总计 8,775 股，授予两名新聘员工。RSU 奖励和股票期权于 2026 年 1 月 14 日根据 Lifecore 与每位员工之间的聘用信授予，并作为每位员工加入 Lifecore 的重要诱因。</p>
</div><p>The RSU awards and stock options were approved by Lifecore’s compensation committee and were granted as inducement equity awards in accordance with Nasdaq Listing Rule 5635(c)(4) under the Inducement Plan.</p>
<div class="lb-trans"><p>RSU 奖励和股票期权由 Lifecore 的薪酬委员会批准，并根据诱导计划作为诱导股权奖励授予，符合纳斯达克上市规则 5635(c)(4)。</p>
</div><p>The RSUs will vest and be settled on the third anniversary of the grant date, subject to continued employment. The stock options have an exercise price equal to Fair Market Value (as defined in the Inducement Plan) on the grant date and will vest as to one-third of the shares on the first anniversary of the grant date and as to 1/36th of the shares on each monthly grant date thereafter, subject to continued employment. The stock options have a seven-year term. The RSU award and stock options are each governed by an award agreement and the Inducement Plan.</p>
<div class="lb-trans"><p>RSU 将在授予日期的第三周年时归属并结算，前提是持续就业。股票期权的行使价格等于授予日期的公允市场价值（如诱导计划中定义），并将在授予日期的第一周年时归属三分之一的股份，之后每个月归属 1/36 的股份，前提是持续就业。股票期权的有效期为七年。RSU 奖励和股票期权均受奖励协议和诱导计划的约束。</p>
</div><p><strong>About Lifecore Biomedical</strong></p>
<div class="lb-trans"><p><strong>关于 Lifecore Biomedical</strong></p>
</div><p>Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.</p>
<div class="lb-trans"><p>Lifecore Biomedical, Inc.（纳斯达克：LFCR）是一家全面整合的合同开发和制造组织（CDMO），在无菌注射药物产品的开发、灌装和封装方面提供高度差异化的能力，包括复杂配方。作为优质注射级透明质酸的领先制造商，Lifecore 凭借超过 40 年的专业知识，成为全球和新兴生物制药及生物技术公司的合作伙伴，帮助他们在多个治疗类别中将创新推向市场。有关公司的更多信息，请访问 Lifecore 的网站 www.lifecore.com。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU56UXdPU00zTXpZMk1qRTRJekl3TURjM05UWT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyNzQwOSM3MzY2MjE4IzIwMDc3NTY="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZDljZDcxYTctZThhMS00NDI5LTg2OGItMjFiNjE2NzNlY2EyLTEwMTkzMjktMjAyNi0wMS0xNi1lbg==/tiny/Lifecore-Biomedical-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ZDljZDcxYTctZThhMS00NDI5LTg2OGItMjFiNjE2NzNlY2EyLTEwMTkzMjktMjAyNi0wMS0xNi1lbg==/tiny/Lifecore-Biomedical-Inc-.png"/></p>
<pre><code>Lifecore Biomedical, Inc. Contact Information:Stephanie Diaz (Investors)Vida Strategic Partners415-675-7401sdiaz@vidasp.comTim Brons (Media)Vida Strategic Partners415-675-7402tbrons@vidasp.comRyan D. Lake (CFO)Lifecore Biomedical952-368-6244ryan.lake@lifecore.com
</code></pre>
<div class="lb-trans"><pre><code>Lifecore Biomedical, Inc. 联系信息：Stephanie Diaz（投资者）Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com Tim Brons（媒体）Vida Strategic Partners 415-675-7402 tbrons@vidasp.com Ryan D. Lake（首席财务官）Lifecore Biomedical 952-368-6244 ryan.lake@lifecore.com
</code></pre>
</div>

Lifecore 宣布根据纳斯达克上市规则 5635(c)(4) 授予诱导性股票奖励 | NBI 股票新闻